Source Name: 2023_Tanada

Literature Information

Literature Title Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
Doi 10.1021/jacs.3c03886
Research Group
  1. Chugai Pharmaceutical Co., Ltd.
  2. -
  3. -
  4. -
  5. -
  6. -
Data Number 38
Minimum Molecular Weight 1257.5
Maximum Molecular Weight 1437.7


Assay Information 1

Assay Type Caco2
Permeability Type logPapp
Membrane Measurement Direction (Exclude PAMPA) Apical to Basolateral (AB)
Assay Detail Caco-2 cells were cultured on a 96-well Transwell® (Corning Inc., NY, US) for 3 weeks, Fasted State Simulated Intestinal Fluids (FaSSIF)/Dulbecco’s Modified Eagle Medium (DMEM) buffer (1% DMSO) containing the compound was added to the Apical side and DMEM was added to the Basal side, and this was pre-incubated at 5% CO2, 37 °C, and 80 rpm for 20–24 h. After pre-incubation, the pre incubation solutions on the Apical side and on the Basal side were removed by aspiration and washed by Hanks' Balanced Salt Solution (HBSS) buffer. Then FaSSIF/HBSS buffer (pH 6.0) containing the compound and 1% DMSO was added to the Apical side, and HBSS buffer containing 4% BSA (pH 7.4) was added to the Basal side, and membrane permeability assays were initiated. Each well was shaken under conditions of 5% CO2, 37 °C, and 80 rpm, and 180 min after initiation, samples on the Basal side were collected, and the amount of compound was determined by LC-MS. From the amount of compounds, the apparent permeability coefficient (Papp) was calculated. Papp = (dQ/dt) x [1/(AxC0)] where (dQ/dt) is the amount of compound transported to the acceptor side per time (nmol/s), A is the surface area of the membrane (cm^2), and C0 is the initial compound concentration in the donor side (μM).


Assay Information 2

Assay Type -
Permeability Type -
Membrane Measurement Direction (Exclude PAMPA) -
Assay Detail -